![Eli Wilner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Eli Wilner
Directeur Général chez Eli Wilner & Co.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Owen M. Lopez | M | 83 |
National Museum of American Art of the Smithsonian
![]() National Museum of American Art of the Smithsonian Other Consumer ServicesConsumer Services The National Museum of American Art of the Smithsonian operates a museum and is ultimately controlled by the Government of the United States of America. The company is based in Washington. | - |
Frederick David Hill | M | - |
National Museum of American Art of the Smithsonian
![]() National Museum of American Art of the Smithsonian Other Consumer ServicesConsumer Services The National Museum of American Art of the Smithsonian operates a museum and is ultimately controlled by the Government of the United States of America. The company is based in Washington. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Shalom Hirschman | M | 85 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Stephen M. Elliston | M | 73 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Barry Kaplan | M | - |
Brandeis University
| 4 ans |
Jerome Kemp | M | - |
Brandeis University
| 4 ans |
Eric Weinstein | M | 71 |
Brandeis University
| 4 ans |
Ralph C. Martin | M | - |
Brandeis University
| 4 ans |
Andrew B. Hahn | M | - |
Brandeis University
| 3 ans |
Michael J. Gresser | M | - |
Brandeis University
| 3 ans |
Michael N. Kahn | M | - |
Brandeis University
| 4 ans |
Fernando Torres-Gil | M | - |
Brandeis University
| 3 ans |
Dan Jick | M | - |
Brandeis University
| 4 ans |
Richard M. Blau | M | - |
Brandeis University
| 4 ans |
Brad Bederman | M | - |
Brandeis University
| 4 ans |
David Segal | M | 68 |
Brandeis University
| 4 ans |
Daniel I. Schlessinger | M | - |
Brandeis University
| 4 ans |
Andy R. Stern | M | - |
Brandeis University
| 4 ans |
Stanley Roth | M | - |
Brandeis University
| 4 ans |
Charalampos A. Makkas | M | 72 |
Brandeis University
| 4 ans |
Larry H. Levy | M | - |
Brandeis University
| 4 ans |
Richard Alexander | M | - |
Brandeis University
| 4 ans |
Windsor N. Hall | M | - |
Brandeis University
| 4 ans |
Adam Henick | M | - |
Hunter College
| 2 ans |
Daniel J. Jick | M | - |
Brandeis University
| 4 ans |
Karen M. Muller | F | 69 |
Hunter College
| 4 ans |
William D. Freedman | M | - |
Brandeis University
| 4 ans |
Christie Hefner | F | 71 |
Brandeis University
| 4 ans |
Perry Traquina | M | 68 |
Brandeis University
| 4 ans |
Jacqueline Sonnabend | F | 69 |
Brandeis University
| 4 ans |
Richard Northern | M | 75 |
Brandeis University
| 3 ans |
Bill Wittenberg | M | - |
Brandeis University
| 4 ans |
Eric Cohen | M | 66 |
Brandeis University
| 4 ans |
Elma Hawkins | M | 67 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
David A. Kadish | M | 71 |
Brandeis University
| 1 ans |
Richard Seth Rosen | M | 66 |
Brandeis University
| 4 ans |
Charles H. Moore | M | 94 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | - |
Curt S. Rush | M | 70 |
Hunter College
| 4 ans |
David Seligman | M | - |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 4 ans |
Nancy J. van Sant | F | - |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 4 ans |
Roy S. Walzer | M | 76 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 7 ans |
Irach Taraporewala | M | 68 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 6 ans |
Candace E. Browning-Platt | F | - |
Brandeis University
| 4 ans |
Gilbert L. Drozdow | M | - |
Brandeis University
| 4 ans |
William J. Kane | M | - |
Brandeis University
| 4 ans |
Joshua Ostroff | M | - |
Brandeis University
| 4 ans |
Angelo S. Botter | M | 76 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | 3 ans |
Wendee Wolfson | F | - |
Brandeis University
| 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 48 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Eli Wilner
- Réseau Personnel